A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

The Consequence Podcast Network series In Defense of Ska shares its name with host Aaron Carnes’ book, the second edition of which arrives this week. To celebrate the updated release, Carnes has put ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...

Commenting on the update, Dr Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, said: “The CDC’s decision to lower ...

In highlighting casdatifan’s potential versus Merck’s approved med ... 10-year deal with Arcus in 2020, paying $175 million upfront for rights to the PD-1 checkpoint inhibitor zimberelimab ...

Today, a brief rundown of news from Merck & Co. and Roche, as well as updates from Sangamo ... Margenza was approved in 2020 together with chemotherapy for adults with metastatic HER2-positive breast ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.